_id

683a163ac782e11e38d1b2a4

id

10198

title

PSA Doubling Time (PSADT) Calculator

full_title

PSA Doubling Time (PSADT) Calculator

short_title

PSA Doubling Time (PSADT) Calculator

med_description

Calculates rate of PSA doubling in prostate cancer (correlates with survival).

short_description

PSA survival.

slug

psa-doubling-time-psadt-calculator

description

The PSA Doubling Time Calculator calculates rate of PSA doubling in prostate cancer (correlates with survival).

keywords

Psa, psa doubling time, psa velocity, rate of rise of psa, PSADT

complaint

[ "Any/All" ]

formula

Prostate-specific antigen doubling time (PSADT) = ln(2) / x, Where x = slope of the relationship between ln(PSA, ng/mL) and time of PSA measurement (i.e., ln(PSAn) - ln(PSA1) / time between PSAnand PSA1, where n refers to a measurement >1)

evidence

PSA doubling time (PSADT) has been studied as a survival measure in prostate cancer. A retrospective review of 304 prostate cancer patients with biochemical recurrence demonstrated that PSA doubling time, Gleason Score, and length of time to biochemical recurrence following surgery were predictive of the risk for development of metastatic disease (Pound 1999). Metastatic disease-free survival was the longest among those with Gleason Scores 5-7, length of time to biochemical recurrence >2 years, and PSADT >10 months.  

measurements

[ { "name": "Days/Months", "unit": "psadt_days", "error_min": "0", "error_max": "5000", "warn_min": "0", "warn_max": "5000", "conversion": "30.4375", "normal_max_si": "0", "normal_max_us": "0", "normal_min_si": "0", "normal_min_us": "0", "units_si": "days", "units_us": "months" }, { "name": "psa", "unit": "psa", "error_min": "0", "error_max": "100", "warn_min": "0", "warn_max": "100", "conversion": "1", "normal_max_si": "0", "normal_max_us": "0", "normal_min_si": "0", "normal_min_us": "0", "units_si": "ng/mL", "units_us": "ng/mL" } ]

information

refrences

{ "Clinical Practice Guidelines": [], "Manufacturer Website": [], "Original/Primary Reference": [ { "href": "https://jamanetwork.com/journals/jama/fullarticle/189741", "text": "Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281(17):1591-7." } ], "Other References": [ { "href": "https://www.ncbi.nlm.nih.gov/pubmed/9302139 ", "text": "Patel A, Dorey F, Franklin J, Dekernion JB. Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J Urol. 1997;158(4):1441-5." }, { "href": "https://www.nccn.org/professionals/physician_gls/default.aspx#prostate", "text": "NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer." } ], "Outcomes": [], "Validation": [], "Validations": [] }

pearls

• For patients with biochemical recurrence of prostate cancer, optimal PSADT calculation should include all PSA values of the individual within two years of initially documented PSA recurrence.

• Entering more values improves accuracy of estimation.

• Shorter PSADT reflects faster increase in PSA levels, while longer PSADT reflects a slower increase in PSA levels over time.

usecase

• Patients with prostate cancer who have undergone radical prostatectomy or definitive radiation therapy and have biochemical recurrence, defined as confirmed PSA ≥0.2 ng/mL if radical prostatectomy or confirmed PSA rise of ≥2 ng/mL above the nadir PSA level if radiation therapy.

• PSADT has limited value in prostate cancer screening or diagnosis.

reasons

In patients with biochemical recurrence, PSADT: Predicts risk of metastasis and risk of dying of prostate cancer when combined with other factors such as theGleason Scoreand length of time to biochemical recurrence. Helps identify patients more likely to develop clinically significant disease. Helps guide patient selection for salvage local therapy or androgen deprivation therapy. Helps guide utilization and timing of imaging studies. For patients with M0 castration resistant disease, PSADT helps guide patient selection for observation, second generation antiandrogen, androgen metabolism inhibitor, or other secondary hormone treatments. Used in assessment of eligibility for clinical trials.

next_advice

• Further management should be individualized based on age, comorbidities, life expectancy, patient preferences, and other relevant factors.

• More detailed information can be found in the National Comprehensive Cancer Network (NCCN) Guidelines.

next_actions

next_management

diseases

[ "Cancer", "Prostate Cancer" ]

input_schema

[ { "conditionality": "", "default": null, "fhir_rules": null, "inct": null, "label_en": "PSA₁", "name": "psa1", "optional": false, "tips_en": "First (earliest) available PSA result", "type": "textbox", "unit": "psa" }, { "conditionality": "", "default": null, "fhir_rules": null, "inct": null, "label_en": "PSA₂", "name": "psa2", "optional": false, "tips_en": "Second available PSA result", "type": "textbox", "unit": "psa" }, { "conditionality": "", "default": null, "fhir_rules": null, "inct": null, "label_en": "Time between PSA₁ and PSA₂ measurement", "name": "time2", "optional": false, "tips_en": "", "type": "textbox", "unit": "psadt_days" }, { "conditionality": "", "default": 0, "label_en": "Add another measurement", "md_calc_info_concept": null, "name": "add1", "option_fhir_rules": null, "optional": false, "options": [ { "label": "No", "value": 0 }, { "label": "Yes", "value": 1 } ], "show_points": false, "tips_en": "", "type": "toggle" }, { "conditionality": "add1>0", "default": null, "fhir_rules": null, "inct": null, "label_en": "PSA₃", "name": "psa3", "optional": false, "tips_en": "Third available PSA result", "type": "textbox", "unit": "psa" }, { "conditionality": "add1>0", "default": null, "fhir_rules": null, "inct": null, "label_en": "Time between PSA₂ and PSA₃ measurement", "name": "time3", "optional": false, "tips_en": "", "type": "textbox", "unit": "psadt_days" }, { "conditionality": "add1>0", "default": 0, "label_en": "Add another measurement", "md_calc_info_concept": null, "name": "add2", "option_fhir_rules": null, "optional": false, "options": [ { "label": "No", "value": 0 }, { "label": "Yes", "value": 1 } ], "show_points": false, "tips_en": "", "type": "toggle" }, { "conditionality": "add2>0", "default": null, "fhir_rules": null, "inct": null, "label_en": "PSA₄", "name": "psa4", "optional": false, "tips_en": "Fourth available PSA result", "type": "textbox", "unit": "psa" }, { "conditionality": "add2>0", "default": null, "fhir_rules": null, "inct": null, "label_en": "Time between PSA₃ and PSA₄ measurement", "name": "time4", "optional": false, "tips_en": "", "type": "textbox", "unit": "psadt_days" }, { "conditionality": "add2>0", "default": 0, "label_en": "Add another measurement", "md_calc_info_concept": null, "name": "add3", "option_fhir_rules": null, "optional": false, "options": [ { "label": "No", "value": 0 }, { "label": "Yes", "value": 1 } ], "show_points": false, "tips_en": "", "type": "toggle" }, { "conditionality": "add3>0", "default": null, "fhir_rules": null, "inct": null, "label_en": "PSA₅", "name": "psa5", "optional": false, "tips_en": "Fifth available PSA result", "type": "textbox", "unit": "psa" }, { "conditionality": "add3>0", "default": null, "fhir_rules": null, "inct": null, "label_en": "Time between PSA₄ and PSA₅ measurement", "name": "time5", "optional": false, "tips_en": "", "type": "textbox", "unit": "psadt_days" } ]

instructions

Use in patients with prostate cancer. Do not use for screening or diagnosis.

published

2022-04-21T20:28:33.524Z

purpose

[ "Formula", "Prognosis" ]

search_terms

[ "Psa", "psa doubling time", "psa velocity", "rate of rise of psa", "PSADT" ]

seo

{ "keywords_en": "Psa, psa doubling time, psa velocity, rate of rise of psa, PSADT", "meta_description_en": "The PSA Doubling Time Calculator calculates rate of PSA doubling in prostate cancer (correlates with survival)." }

specialty

[ "Hematology and Oncology", "Urology" ]

departments

[ "Genitourinary", "Oncologic", "Reproductive", "Urinary" ]

tags

[]

version_number

1

versions

[]

related

[ { "calcId": 2049, "short_title_en": "D'Amico Classification", "slug": "damico-risk-classification-prostate-cancer" }, { "calcId": 2076, "short_title_en": "Prostate Tumor Volume", "slug": "prostate-tumor-volume-density" }, { "calcId": 10039, "short_title_en": "CASPAR Criteria for PsA", "slug": "caspar-criteria-psoriatic-arthritis" } ]

ismed

true

section

[ "whenToUseViewed", "pearlsPitfallsViewed", "whyUseViewed", "nextStepsViewed", "evidenceViewed" ]

cleaned_departments

[ "urology", "oncology", "gynecology", "urology" ]

cleaned_use

[ "Patients with prostate cancer who have undergone radical prostatectomy or definitive radiation therapy and have biochemical recurrence, defined as confirmed PSA ≥0.2 ng/mL if radical prostatectomy or confirmed PSA rise of ≥2 ng/mL above the nadir PSA level if radiation therapy.", "PSADT has limited value in prostate cancer screening or diagnosis." ]

pub

false